Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Dose reduction of concomitant glucose-lowering medications may be necessary
Main P, Angley MT, O'Doherty CE, Thomas P, Fenech M
offer designed to help new self-paying patients previously prescribed unapproved "semaglutide" start on FDA-approved Wegovy "Choose the Real Thing" campaign launching to raise awareness about the dangers of knockoff "semaglutide" Novo Nordisk intensifies legal actions aimed at protecting patients from risks and dangers associated with compounded "semaglutide" drugs and their foreign illicit active ingredients PLAINSBORO, N.J., May 22, 2025 /PRNewswire/ -- Today, as the US Food and Drug Administration (FDA) grace period for mass compounding of "semaglutide" expires, Novo Nordisk announced a series of initiatives to further support patient access to authentic, FDA-approved Wegovy (semaglutide) injection 2.4 mg
Common injection sites include the abdomen, thigh, or upper arm, and your provider will instruct you on the correct injection technique and site rotation
